Your product is in clinical phase
III, and your marketing team is preparing for launch? In these
situations, our clients rely on the “BASES Rx Forecaster”
service to support a successful launch planning. This service
provides your team with critical insights in three important
metrics:
1. Volume Potential
Developed by analyzing
actual physician response and by marrying that response to in-market
behavior, this BASES service provides reliable forecasts for the market
potential of a new therapy.
The thorough
volumetric assessment of a new product launch includes:
- Sensitivity analysis on
marketing plans, managed care, competitive impact
et al.
- Period by period volume build,
throughout Year III.
- Volume contribution from physician
and patient types.


2. Normative Database Benchmarking
Customers’ (physicians, patients, or other relevant Health Care providers)
interest in a new drug is captured via a core set of questions, commonly
referred to as BASES Key Measures. BASES R&D shows that these Key
Measures are systematically linked to actual in-market behavior. As
these Key Measures are consistently used in every BASES project, results
can be data-based and compared across studies, categories and countries.
Normative database benchmarking effectively
allows for evaluating overall strength and opportunities for
improvements of new products.
Also, database results indicate potential
volume levers: While physicians might indicate the
desire to write your therapy, their claimed speed of adoption might be
relatively low -- does this indicate that physicians are concerned about
the efficacy of the therapy? Or, are they more worried about your side
effects? Or, are they just satisfied with the current suite of therapies
in the treatment area? BASES' analytical team will help you understand
why the data is what it is.


3. Diagnostics
With the diagnostic analysis, BASES provides
you and your marketing team with a thorough understanding about
what drives or limits physicians interest, and thus gives
marketers and brand teams insights in how to optimize the
message to physicians or consumers.
Common diagnostic
issues we explore:
- Understanding from which competitors
the new drug will most likely source volume from.
- How physicians perceive the new
therapy compared to competition? How does the new drug differentiates itself
from competition?
- Which attributes/benefits most
strongly affect physicians’ adoption, and
on which attributes should communication focus on to maximize
prescribing/usage levels?
